Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4165967 | 0.99 | KDM4E (0.42) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4169299 | 0.85 | SMN1; SMN2 (0.44) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| Bromide SCHEMBL7554050 | 0.84 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4170737 | 0.84 | CA12 (0.39) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL5254676 | 0.82 | CYP3A4 (0.39) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4163641 | 0.82 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL6219463 | 0.80 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL5656859 | 0.77 | KDM4E (0.43) | KDM4EMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL5261078 | 0.77 | CYP3A4 (0.34) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL20345418 | 0.76 | KDM4E (0.42) | KDM4EMAPTALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | ALPI, PYGL, PPIP5K2 | CYP3A4 215/4885CYP2C9 1357/4885CYP2D6 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.